--- title: "Kodiak Sciences (NASDAQ:KOD) Posts Earnings Results, Beats Estimates By $0.06 EPS" description: "Kodiak Sciences (NASDAQ:KOD) reported quarterly earnings of ($0.84) per share, surpassing analysts' expectations of ($0.87) by $0.03. The stock opened at $3.06, with a market cap of $161.03 million. J" type: "news" locale: "en" url: "https://longbridge.com/en/news/233694923.md" published_at: "2025-03-28T21:47:14.000Z" --- # Kodiak Sciences (NASDAQ:KOD) Posts Earnings Results, Beats Estimates By $0.06 EPS > Kodiak Sciences (NASDAQ:KOD) reported quarterly earnings of ($0.84) per share, surpassing analysts' expectations of ($0.87) by $0.03. The stock opened at $3.06, with a market cap of $161.03 million. Jefferies Financial Group upgraded Kodiak Sciences from "hold" to "buy" with a target price of $20.00. The company focuses on developing therapeutics for retinal diseases, with its lead product candidate in advanced clinical studies. Kodiak Sciences (NASDAQ:KOD - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.06, Zacks reports. Get **Kodiak Sciences** alerts: ## Kodiak Sciences Stock Performance NASDAQ:KOD opened at $3.06 on Friday. The stock has a 50-day simple moving average of $4.93 and a 200 day simple moving average of $5.40. Kodiak Sciences has a 52-week low of $2.19 and a 52-week high of $11.60. The company has a market cap of $161.03 million, a PE ratio of -0.84 and a beta of 2.26. ## Wall Street Analyst Weigh In Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 target price on the stock in a research note on Monday, December 9th. **Read Our Latest Stock Report on KOD** ## Kodiak Sciences Company Profile (Get Free Report) Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. ## Featured Articles - Five stocks we like better than Kodiak Sciences - What Are Dividends? Buy the Best Dividend Stocks - Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell - What is Short Interest? How to Use It - Top 3 Beverage Stocks Pouring Out Profits - Utilities Stocks Explained – How and Why to Invest in Utilities - CarMax and Carvana: Steering the Used Car Market ## Should You Invest $1,000 in Kodiak Sciences Right Now? Before you consider Kodiak Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list. While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [KOD.US - Kodiak Sciences](https://longbridge.com/en/quote/KOD.US.md) - [JEF.US - Jefferies Financial](https://longbridge.com/en/quote/JEF.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | GSA Capital Partners LLP Sells 76,735 Shares of Kodiak Sciences Inc. $KOD | GSA Capital Partners LLP has reduced its stake in Kodiak Sciences Inc. by 46.7%, selling 76,735 shares in Q3, leaving it | [Link](https://longbridge.com/en/news/276216383.md) | | Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Insider Buying Activity | Kodiak Sciences (NASDAQ:KOD) shares rose after insider buying activity. Director Bros. Advisors Lp Baker purchased 2,608 | [Link](https://longbridge.com/en/news/270511656.md) | | A Utility Stock with Steady Earnings and a Dividend Higher Than a 30 Year T-Bill | A Utility Stock with Steady Earnings and a Dividend Higher Than a 30 Year T-Bill | [Link](https://longbridge.com/en/news/276353070.md) | | Deadliest jobs in America revealed | In 2024, the U.S. recorded 5,070 fatal work injuries, a 4% decrease from 2023. Truck drivers and construction workers we | [Link](https://longbridge.com/en/news/276462715.md) | | BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) \| BBIO Stock News | BridgeBio Pharma, Inc. announced the approval of equity grants to 34 new employees, totaling 76,701 shares of common sto | [Link](https://longbridge.com/en/news/276181414.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.